This is the story of a medical technology spin-out company from a UK university which develops regenerative solutions for the problems of ageing and disease. The company’s value proposition is that it has been developing solutions which do not need to be cryogenically stored and that potentially adapt to younger patients who are still growing. The company has successfully performed implantation testing to ascertain the functionality of its heart valves in collaboration with university partners in the UK and South America. The OI project has been an important step to undertaking full clinical trials of its heart valve products.